References
- Grabowski H, Vernon J. Longer patents for lower imitation barriers: the 1984 drug act. Amer Econ Rev 1986;76:195-8
- Berndt E. Pharmaceuticals in U.S. health care: determinants of quantity and price. J Econ Perspect 2002;16:45-66
- Office of the Assistant Secretary for Planning and Evaluation (ASPE Issue Brief). Expanding the use of generic drugs. Washington, DC: ASPE, 2010. www.aspe.hhs.gov/sp/reports/2010/genericdrugs/ib.pdf. Accessed 2, October 2013
- Medicines use and spending shifts: a review of the use of medicines in the U.S. in 2014. IMS Institute for Healthcare Informatics. www.theimsinstitute.org/en/thought-leadership/ims-institute/reports/medicines-use-in-the-us-2014#ims-form. Accessed 14, December 2015
- Panattoni LE. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms. J Health Econ 2011;30:126-45
- Smith K, Gleklen K. Generic drugmakers will challenge patents even when they have a 97% chance of losing: the FTC Report that K-Dur ignored. CPI Antitrust Chronicle, 2012. www.competitionpolicyinternational.com/generic-drugmakers-will-challenge-patents-even-when-they-have-a-97-chance-of-losing-the-ftc-report-that-k-dur-ignored/. Accessed 3, October 2013
- Glass G. Legal defenses and outcomes in paragraph IV patent litigation. J Generic Med 2013;10:4-13
- Grabowski H, Kyle M. Generic competition and market exclusivity periods in pharmaceuticals. Manage Decis Econ 2007;28:491-502
- Grabowski H, Kyle M, Mortimer R, et al. Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act. Health Affairs 2011;30:2157-66
- Grabowski H, Long G, Mortimer R, Recent trends in brand name and generic drug competition. J Med Econ 2014;17:207-14
- Grabowski H, Brain C, Taub A, et al. Pharmaceutical patent challenges: company strategies and litigation outcomes. Am J Health Econ (forthcoming)